Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 7/2020

01-07-2020 | Prostate Cancer | Special Section: Male pelvis

Positron emission tomography (PET) radiotracers for prostate cancer imaging

Authors: Stephanie M. Walker, Ilhan Lim, Liza Lindenberg, Esther Mena, Peter L. Choyke, Baris Turkbey

Published in: Abdominal Radiology | Issue 7/2020

Login to get access

Abstract

Imaging plays an increasing role in prostate cancer diagnosis and staging. Accurate staging of prostate cancer is required for optimal treatment planning. In detecting extraprostatic cancer and sites of early recurrence, traditional imaging methods (computed tomography, magnetic resonance imaging, radionuclide bone scan) have suboptimal performance. This leaves a gap between known disease recurrence as indicated by rising prostate-specific antigen and the ability to localize the recurrence on imaging. Novel positron emission tomography (PET) agents including radiolabeled choline, fluciclovine (18F-FACBC), and agents targeting prostate-specific membrane antigen are being developed and tested to increase diagnostic performance of non-invasive prostate cancer localization. When combined with CT or MRI, these tracers offer a combination of functional information and anatomic localization that is superior to conventional imaging methods. These PET radiotracers have varying mechanisms and excretion patterns affecting their pharmacokinetics and diagnostic performance, which will be reviewed in this article.
Literature
1.
Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. 2019. 69(1): p. 7-34.
2.
Li, R., et al., The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018. 21(1): p. 4-21.PubMed
3.
De Bruycker, A., et al., Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. 2017. 120(6): p. 815-821.
4.
Giannarini, G., et al., Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer? European Urology, 2018. 74(2): p. 131-133.PubMed
5.
Jadvar, H., Molecular imaging of prostate cancer: PET radiotracers. AJR. American journal of roentgenology, 2012. 199(2): p. 278-291.PubMedPubMedCentral
6.
Bednarova, S., et al., Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. 2017, 2017. 6(3): p. 413-423.
7.
Almuhaideb, A., N. Papathanasiou, and J. Bomanji, 18F-FDG PET/CT imaging in oncology. Annals of Saudi medicine, 2011. 31(1): p. 3-13.PubMedPubMedCentral
8.
9.
Picchio, M., et al., Value of [11C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [18F]fluorodeoxyglucose-Positron Emission Tomography. The Journal of Urology, 2003. 169(4): p. 1337-1340.PubMed
10.
Ackerstaff, E., et al., Detection of Increased Choline Compounds with Proton Nuclear Magnetic Resonance Spectroscopy Subsequent to Malignant Transformation of Human Prostatic Epithelial Cells. 2001. 61(9): p. 3599-3603.
11.
Wallitt, K.L., et al., Clinical PET Imaging in Prostate Cancer. 2017. 37(5): p. 1512-1536.
12.
Umbehr, M.H., et al., The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2013. 64(1): p. 106-117.PubMed
13.
Cimitan, M., et al., [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging, 2006. 33(12): p. 1387-1398.PubMed
14.
Jadvar, H., Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011. 52(1): p. 81-89.
15.
Fuccio, C., et al., Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Annals of Nuclear Medicine, 2010. 24(6): p. 485-492.PubMed
16.
Hövels, A.M., et al., The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology, 2008. 63(4): p. 387-395.PubMed
17.
Evangelista, L., et al., Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis. 2013. 38(5): p. 305-314.PubMed
18.
Guo, Y., et al., Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis. PLOS ONE, 2018. 13(9): p. e0203400.PubMedPubMedCentral
19.
Giovacchini, G., et al., Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010. 37(2): p. 301-309.PubMed
20.
Castellucci, P., et al., Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? European Journal of Nuclear Medicine and Molecular Imaging, 2011. 38(1): p. 55-63.
21.
Sakata, T., et al., L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathology International, 2009. 59(1): p. 7-18.PubMed
22.
Oka, S., et al., A preliminary study of anti-1-amino-3-F-18-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. Journal of Nuclear Medicine, 2007. 48(1): p. 46-55.PubMed
23.
Savir-Baruch, B., et al., Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. American Journal of Roentgenology, 2019: p. 1-8.
24.
Odewole, O.A., et al., Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging, 2016. 43(10): p. 1773-83.PubMedPubMedCentral
25.
Kim, S.J. and S.W. Lee, The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis. Clinical Radiology, 2019.
26.
Turkbey, B., et al., Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology, 2014. 270(3): p. 849-56.PubMed
27.
Selnaes, K.M., et al., (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol, 2018. 28(8): p. 3151-3159.PubMed
28.
Pernthaler, B., et al., A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68 Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. 2019. 44(10): p. e566-e573.
29.
Nanni, C., et al., 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. 2015. 40(8): p. e386-e391.
30.
Wright, G.L., et al., Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology: Seminars and Original Investigations, 1995. 1(1): p. 18-28.PubMed
31.
Martin, K.B., et al., Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-Related Cancer, 2019. 26(2): p. 131-146.
32.
Prasad, V., et al., Biodistribution of [68 Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Molecular Imaging and Biology, 2016. 18(3): p. 428-436.PubMed
33.
Koerber, S.A., et al., (68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. J Nucl Med, 2018.
34.
Calais, J., et al., (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol, 2019. 20(9): p. 1286-1294.PubMed
35.
Afshar-Oromieh, A., et al., Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging, 2017. 44(8): p. 1258-1268.PubMedPubMedCentral
36.
Fendler, W.P., et al., Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol, 2019. 5(6): p. 856-863.PubMedPubMedCentral
37.
Afshar-Oromieh, A., et al., Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging, 2018. 45(12): p. 2045-2054.PubMedPubMedCentral
38.
Sterzing, F., et al., 68 Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016. 43(1): p. 34-41.PubMed
39.
Gorin, M.A., M.G. Pomper, and S.P. Rowe, PSMA-targeted imaging of prostate cancer: the best is yet to come. 2016. 117(5): p. 715-716.
40.
Sanchez-Crespo, A., Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Applied Radiation and Isotopes, 2013. 76: p. 55-62.PubMed
41.
Dietlein, M., et al., Comparison of [18F]DCFPyL and [68 Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology, 2015. 17(4): p. 575-584.PubMedPubMedCentral
42.
Czarniecki, M., et al., Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. 2018, 2018. 7(5): p. 831-843.
43.
Rowe, S.P., et al., Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med, 2016. 57(1): p. 46-53.PubMed
44.
Harmon, S.A., et al., A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-Targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med, 2018. 59(11): p. 1665-1671.PubMedPubMedCentral
45.
Wondergem, M., et al., 18F-DCFPyL PET/CT in primary staging of prostate cancer. 2018. 2(1): p. 26.
46.
Rowe, S.P., et al., Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. J Nucl Med, 2019.
47.
Rowe, S.P., et al., PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016. 18(3): p. 411-419.PubMedPubMedCentral
48.
Giesel, F.L., et al., Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med, 2019. 60(3): p. 362-368.PubMedPubMedCentral
49.
Kesch, C., et al., Intra-individual comparison of (18)F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. 58.
50.
Werner, R.A., et al., 18 F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020. 10(1): p. 1-16.PubMedPubMedCentral
51.
Dietlein, M., et al., Performance of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. 2018. 59(supplement 1): p. 452.
52.
Behr, S.C., et al., First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. 2018.
53.
Saga, T., et al., Initial evaluation of PET/CT with 18F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients. 2019. 110(2): p. 742.
54.
Alonso, O., et al., PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68 Ga-PSMA-HBED-CC. 2018. 59(supplement 1): p. 1499-1499.
55.
Fraum, T.J., et al., Prostate cancer PET tracers: essentials for the urologist. Can J Urol, 2018. 25(4): p. 9371-9383.PubMed
56.
Czernin, J., N. Satyamurthy, and C. Schiepers, Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med, 2010. 51(12): p. 1826-9.PubMedPubMedCentral
57.
Sheikhbahaei, S., et al., 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine, 2019. 33(5): p. 351-361.PubMed
58.
Chen, B., et al., Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. 2019. 40(9): p. 940-946.
59.
Beheshti, M., et al., Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med, 2016. 57(Suppl 3): p. 55S-60S.PubMed
60.
Schirrmeister, H., Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am, 2007. 45(4): p. 669-76, vi.
61.
Jadvar, H. and P.M. Colletti, 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. The British Journal of Radiology, 2018. 91(1091): p. 20170948.PubMedPubMedCentral
62.
Poeppel, T.D., et al., 68 Ga-DOTATOC versus 68 Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med, 2011. 52(12): p. 1864-70.PubMed
63.
Morichetti, D., et al., Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol, 2010. 23(2): p. 511-22.PubMed
64.
Gofrit, O.N., et al., PET/CT With 68 Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer. 2017. 42(1): p. 1-6.
65.
dos Santos, G., et al., Comparación intraindividual de la PET/TC con 68 Ga-DOTATATE vs. PET/TC con 11C-colina en pacientes con cáncer de próstata en recaída bioquímica: evaluación in vivo de la expresión de receptores de la somatostatina. Revista Española de Medicina Nuclear e Imagen Molecular, 2019. 38(1): p. 29-37.
66.
Wang, J., 68 Ga-DOTATATE in Benign Prostate Hyperplasia. 2019. 44(3): p. 249-250.
Metadata
Title
Positron emission tomography (PET) radiotracers for prostate cancer imaging
Authors
Stephanie M. Walker
Ilhan Lim
Liza Lindenberg
Esther Mena
Peter L. Choyke
Baris Turkbey
Publication date
01-07-2020
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02427-4

Other articles of this Issue 7/2020

Abdominal Radiology 7/2020 Go to the issue

Special Section: Distinguished Papers from JSAR

MRI features of the nested variant of urothelial carcinoma of the urinary bladder: report of four cases

Special Section: Male pelvis

Imaging of the adult male urethra, penile prostheses and artificial urinary sphincters

Review

MRI findings of nonobstructive azoospermia: lesions in and out of pelvic cavity

Special Section: Male pelvis

Post-treatment prostate MRI

Special Section: Male pelvis

Utility of dynamic MRA in the evaluation of male erectile dysfunction

Special Section: Distinguished Papers from JSAR

Uterine adenomatoid tumor associated with lymph node lesions: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits